Finerenone, a selective nonsteroidal glucocorticoid receptor antagonist, has been shown to improve markers of renal and cardiovascular injury in patients with T2DM and CKD in both animal and phase 2 trials. Here, NR3C1 is linked to chronic kidney disease.